MCID: ACR007
MIFTS: 71

Acromegaly

Categories: Endocrine diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Acromegaly

MalaCards integrated aliases for Acromegaly:

Name: Acromegaly 12 76 53 59 37 13 55 44 15 73
Growth Hormone Excess 53 29
Growth Hormone-Secreting Pituitary Adenoma 73
Somatotroph Adenoma 53
Pituitary Giant 53

Characteristics:

Orphanet epidemiological data:

59
acromegaly
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of),1-9/1000000 (Iceland),1-5/10000 (Iceland); Age of onset: Adult;

Classifications:



Summaries for Acromegaly

NIH Rare Diseases : 53 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (GH). It is most often diagnosed in middle-aged adults, although symptoms can appear at any age. Signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that; alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. The condition is usually caused by benign tumors on the pituitary called adenomas. Rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain stimulating the pituitary gland to produce GH. It is sporadic in 95% of the cases, but almost 50% of the childhood-onset cases have an identifiable genemutation, most commonly in the AIP gene or GPR101 gene. Treatment may include hormones, radiotherapy, and surgery. When left untreated, it can result in serious illness and premature death. When GH-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly.   Acromegaly may also be part of other genetic syndromes such as multiple endocrine neoplasia syndrome type 1 and type 4, hereditary paraganglioma-pheochromocytoma syndrome, McCune-Allright syndrome, neurofibromatosis or Carney complex. 

MalaCards based summary : Acromegaly, also known as growth hormone excess, is related to pituitary adenoma 1, multiple types and gigantism. An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and Metabolism of proteins. The drugs Pasireotide and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and testes, and related phenotypes are frontal bossing and osteoarthritis

Disease Ontology : 12 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia : 76 Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have... more...

Related Diseases for Acromegaly

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 1, multiple types 33.2 AIP GH1 IGF1 IGFBP3 PRL SST
2 gigantism 32.2 AIP GH1 GHRH GPR101 PRL
3 pituitary tumors 31.0 AIP GH1 GNAS IGF1 MEN1 POMC
4 pituitary apoplexy 30.6 AIP INS POMC PRL
5 mccune-albright syndrome 30.5 GH1 GNAS IGF1 PRL SST
6 sleep apnea 30.5 GHRL IGF1 INS
7 galactorrhea 30.5 IGF1 PRL
8 growth hormone deficiency 30.4 GH1 GHRH GHRL IGF1 IGFBP3
9 bronchial adenomas/carcinoids childhood 30.3 POMC SST
10 dwarfism 30.2 GH1 GHR GHRH
11 fibrous dysplasia 30.2 GH1 GNAS IGF1 PRL SST
12 amenorrhea 30.1 POMC PRL TRH
13 carcinoid syndrome 30.1 GHRH IGF1 MEN1 SST
14 hyperprolactinemia 30.1 GH1 IGF1 POMC PRL SST TRH
15 fibrous dysplasia/mccune-albright syndrome 30.1 GH1 PRL
16 acanthosis nigricans 30.1 IGF1 INS PRL
17 diabetes mellitus 30.0 GHRL IGF1 IGFBP1 INS MEN1 SST
18 hypopituitarism 30.0 GH1 GHRH IGF1 IGFBP3 INS POMC
19 empty sella syndrome 29.9 GH1 IGF1 POMC PRL TRH
20 glucose intolerance 29.9 GHRL IGF1 IGFBP1 INS
21 pituitary infarct 29.9 IGF1 POMC PRL SST
22 microvascular complications of diabetes 1 29.9 IGF1 IGFBP3 INS SST
23 pituitary adenoma, prolactin-secreting 29.8 AIP GH1 GNAS IGF1 MEN1 POMC
24 insulin-like growth factor i 29.8 GH1 GHR GHRH IGF1 IGF2 IGFBP1
25 hypothalamic disease 29.8 GH1 GHRH POMC PRL
26 nelson syndrome 29.8 POMC PRL SST
27 osteoporosis 29.8 GH1 GHR IGF1 IGFBP3 INS
28 pituitary carcinoma 29.8 GNAS POMC PRL SST
29 diabetes insipidus 29.8 INS POMC PRL
30 ovarian disease 29.8 IGF1 IGFBP1 INS PRL
31 postural hypotension 29.7 INS SST
32 neuroendocrine tumor 29.7 MEN1 SST SSTR2
33 isolated growth hormone deficiency 29.7 GH1 GHR GHRH IGF1
34 conn's syndrome 29.7 GH1 GNAS MEN1 POMC PRL SST
35 hypothyroidism 29.7 GH1 GNAS IGF1 IGFBP3 POMC PRL
36 acidophil adenoma 29.6 IGF1 POMC SST
37 lymphocytic hypophysitis 29.6 GH1 POMC
38 zollinger-ellison syndrome 29.6 GHRH MEN1 SST
39 diffuse idiopathic skeletal hyperostosis 29.6 IGF1 IGFBP3
40 craniopharyngioma 29.6 GH1 GHRL IGF1 INS PRL TRH
41 growth hormone secreting pituitary adenoma 29.5 AIP GNAS PRL SST SSTR2
42 islet cell tumor 29.5 IGF2 INS MEN1 SST
43 polycystic ovary syndrome 29.5 IGF1 IGFBP1 INS PRL
44 adenoma 29.5 AIP GH1 GNAS GPR101 IGF1 MEN1
45 chronic kidney failure 29.5 IGF1 IGFBP1 IGFBP3 INS
46 multiple endocrine neoplasia, type i 29.4 GHRH GNAS INS MEN1 PRL SST
47 turner syndrome 29.4 GH1 GHR IGF1 IGFBP1 IGFBP3
48 carney complex variant 29.4 AIP GNAS MEN1
49 chromophobe adenoma 29.4 GH1 GHRH INS POMC PRL TRH
50 glucose metabolism disease 29.3 GHRL IGF1 INS POMC SST

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to Acromegaly

Symptoms & Phenotypes for Acromegaly

Human phenotypes related to Acromegaly:

59 32 (show top 50) (show all 58)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 frontal bossing 59 32 frequent (33%) Frequent (79-30%) HP:0002007
2 osteoarthritis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002758
3 depressivity 59 32 frequent (33%) Frequent (79-30%) HP:0000716
4 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
5 hypertension 59 32 frequent (33%) Frequent (79-30%) HP:0000822
6 hyperhidrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000975
7 kyphosis 59 32 frequent (33%) Frequent (79-30%) HP:0002808
8 sleep apnea 59 32 frequent (33%) Frequent (79-30%) HP:0010535
9 macroglossia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000158
10 coarse facial features 59 32 hallmark (90%) Very frequent (99-80%) HP:0000280
11 mandibular prognathia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000303
12 macrotia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000400
13 widely spaced teeth 59 32 frequent (33%) Frequent (79-30%) HP:0000687
14 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
15 joint swelling 59 32 hallmark (90%) Very frequent (99-80%) HP:0001386
16 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
17 hypertrophic cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001639
18 full cheeks 59 32 hallmark (90%) Very frequent (99-80%) HP:0000293
19 acanthosis nigricans 59 32 occasional (7.5%) Occasional (29-5%) HP:0000956
20 thick lower lip vermilion 59 32 hallmark (90%) Very frequent (99-80%) HP:0000179
21 generalized hirsutism 59 32 frequent (33%) Frequent (79-30%) HP:0002230
22 acne 59 32 occasional (7.5%) Occasional (29-5%) HP:0001061
23 anxiety 59 32 frequent (33%) Frequent (79-30%) HP:0000739
24 abnormality of the fingernails 59 32 frequent (33%) Frequent (79-30%) HP:0001231
25 anterior hypopituitarism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000830
26 migraine 59 32 frequent (33%) Frequent (79-30%) HP:0002076
27 paresthesia 59 32 frequent (33%) Frequent (79-30%) HP:0003401
28 palpebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0100540
29 broad forehead 59 32 hallmark (90%) Very frequent (99-80%) HP:0000337
30 mitral regurgitation 59 32 occasional (7.5%) Occasional (29-5%) HP:0001653
31 long face 59 32 hallmark (90%) Very frequent (99-80%) HP:0000276
32 pituitary prolactin cell adenoma 59 32 frequent (33%) Frequent (79-30%) HP:0006767
33 spinal canal stenosis 59 32 frequent (33%) Frequent (79-30%) HP:0003416
34 hoarse voice 59 32 frequent (33%) Frequent (79-30%) HP:0001609
35 long penis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000040
36 cerebral palsy 59 32 frequent (33%) Frequent (79-30%) HP:0100021
37 synophrys 59 32 frequent (33%) Frequent (79-30%) HP:0000664
38 generalized hyperpigmentation 59 32 occasional (7.5%) Occasional (29-5%) HP:0007440
39 wide nose 59 32 hallmark (90%) Very frequent (99-80%) HP:0000445
40 large hands 59 32 hallmark (90%) Very frequent (99-80%) HP:0001176
41 tapered finger 59 32 hallmark (90%) Very frequent (99-80%) HP:0001182
42 tall stature 59 32 hallmark (90%) Very frequent (99-80%) HP:0000098
43 abnormal toenail morphology 59 32 frequent (33%) Frequent (79-30%) HP:0008388
44 impotence 59 32 occasional (7.5%) Occasional (29-5%) HP:0000802
45 broad foot 59 32 hallmark (90%) Very frequent (99-80%) HP:0001769
46 deep plantar creases 59 32 hallmark (90%) Very frequent (99-80%) HP:0001869
47 cortical diaphyseal thickening of the upper limbs 59 32 hallmark (90%) Very frequent (99-80%) HP:0003859
48 macrodactyly 59 32 hallmark (90%) Very frequent (99-80%) HP:0004099
49 deep palmar crease 59 32 hallmark (90%) Very frequent (99-80%) HP:0006191
50 broad jaw 59 32 frequent (33%) Frequent (79-30%) HP:0012802

GenomeRNAi Phenotypes related to Acromegaly according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 GHR GHRL GNAS IGF1 IGF2 IGFBP3

MGI Mouse Phenotypes related to Acromegaly:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 AIP GHR GHRH GHRL GNAS IGF1
2 endocrine/exocrine gland MP:0005379 10.3 AIP GHR GHRH GHRL GNAS IGF1
3 growth/size/body region MP:0005378 10.25 AIP GHR GHRH GNAS IGF1 IGF2
4 behavior/neurological MP:0005386 10.24 GHR GHRL GNAS IGF2 IGFBP3 INS
5 cardiovascular system MP:0005385 10.22 AIP GHR GNAS GPR101 IGF1 IGF2
6 immune system MP:0005387 10.11 GHR GHRH GNAS IGF1 IGF2 IGFBP1
7 adipose tissue MP:0005375 10.05 GHR GHRL GNAS IGF1 IGFBP3 INS
8 liver/biliary system MP:0005370 10 AIP GHR GHRH GNAS IGF2 IGFBP1
9 integument MP:0010771 9.97 AIP GHR GNAS IGF1 IGF2 IGFBP3
10 nervous system MP:0003631 9.77 GHR GHRH GNAS IGF1 IGF2 INS
11 neoplasm MP:0002006 9.63 AIP GNAS IGF1 MEN1 POMC PRL
12 renal/urinary system MP:0005367 9.17 GHR GNAS IGF1 IGF2 IGFBP3 INS

Drugs & Therapeutics for Acromegaly

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
2
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
3
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
4 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
5
Mecasermin Approved, Investigational Phase 4,Phase 3,Not Applicable 68562-41-4
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Metformin Approved Phase 4 657-24-9 14219 4091
10
Zinc Approved, Investigational Phase 4 7440-66-6
11
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Mitogens Phase 4,Phase 3,Phase 2,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 insulin Phase 4,Phase 3,Phase 2,Not Applicable
19 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Complement Factor I Phase 4,Phase 3
22 Incretins Phase 4
23 Liver Extracts Phase 4
24 Dopamine agonists Phase 4,Phase 3
25 Peripheral Nervous System Agents Phase 4,Phase 2
26 Dopamine Agents Phase 4,Phase 3,Phase 2
27 Autonomic Agents Phase 4,Phase 2
28 Antiparkinson Agents Phase 4,Phase 3
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
30 Sympathomimetics Phase 4,Phase 2
31 Cardiotonic Agents Phase 4,Phase 2
32 Protective Agents Phase 4,Phase 2
33 Sitagliptin Phosphate Phase 4
34 Dipeptidyl-Peptidase IV Inhibitors Phase 4
35
protease inhibitors Phase 4
36 HIV Protease Inhibitors Phase 4
37 Hypoglycemic Agents Phase 4,Phase 2,Not Applicable
38
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
39 Pharmaceutical Solutions Phase 3
40 Carboxymethylcellulose Sodium Phase 3
41 Edotreotide Phase 3
42 Radiopharmaceuticals Phase 3
43
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
44
Dimenhydrinate Approved Phase 2 523-87-5 441281
45
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Not Applicable 77-92-9 311
47
Enclomiphene Investigational Phase 2 15690-57-0
48 Ethinyl estradiol, levonorgestrel drug combination Phase 2
49 Estrogens Phase 2,Not Applicable
50 Clomiphene Phase 2

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
2 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
3 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
4 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
5 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
6 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
7 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
8 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
9 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
10 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
11 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
12 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
13 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
14 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
15 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
16 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
17 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
18 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
19 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
20 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
21 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
22 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
23 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
24 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
25 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
26 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
27 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
28 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed NCT02354508 Phase 3 Pasireotide LAR
29 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
30 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
31 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
32 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3 Octreotide LAR
33 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
34 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
35 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
36 Long Term Study With B2036-PEG Completed NCT00143416 Phase 3 Pegvisomant
37 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension
38 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
39 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3 Octreotide LAR
40 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
41 Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Completed NCT00234572 Phase 2, Phase 3 Lanreotide (Autogel formulation)
42 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
43 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
44 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
45 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
46 Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Completed NCT00210457 Phase 3 Lanreotide (Autogel formulation)
47 Strict IGF-1 Control in Acromegaly Recruiting NCT02952885 Phase 3 Pegvisomant
48 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Recruiting NCT02685709 Phase 3 Octreotide capsules;Injectable Somatostatin Analogs (octreotide or lanreotide);Cabergoline
49 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
50 Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Active, not recruiting NCT03252353 Phase 3 octreotide capsules;Matching placebo

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

Genetic tests related to Acromegaly:

# Genetic test Affiliating Genes
1 Growth Hormone Excess 29

Anatomical Context for Acromegaly

MalaCards organs/tissues related to Acromegaly:

41
Pituitary, Bone, Testes, Brain, Thyroid, Lung, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Acromegaly:

19
Limb

Publications for Acromegaly

Articles related to Acromegaly:

(show top 50) (show all 2224)
# Title Authors Year
1
Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma. ( 29895074 )
2018
2
Transsphenoidal surgery for elderly patients with acromegaly and its outcomes: comparison with younger patients. ( 29966777 )
2018
3
Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly with the GH Receptor Antagonist Pegvisomant. ( 29371335 )
2018
4
Predictors of surgical outcome and early criteria of remission in acromegaly-some controversial issues. ( 29943363 )
2018
5
Management of acromegaly: an exploratory survey of physicians from the Middle East and North Africa. ( 29971605 )
2018
6
Metabolic Complications of Acromegaly. ( 29895013 )
2018
7
Correction to: Pegvisomant in acromegaly: an update. ( 29285678 )
2018
8
Spontaneous improvement of cutis verticis gyrata secondary to acromegaly following surgical treatment of pituitary adenoma. ( 29927514 )
2018
9
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. ( 29789410 )
2018
10
The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly. ( 29890543 )
2018
11
Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly. ( 29782043 )
2018
12
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. ( 29388045 )
2018
13
Pasireotide in acromegaly by aggressive tumors, description of four clinical cases. Towards a personalized medicine. ( 29371000 )
2018
14
Effects of active acromegaly on bone mRNA and microRNA expression patterns. ( 29374071 )
2018
15
Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches. ( 29925553 )
2018
16
CyberKnife robotic radiosurgery in the multimodal management of acromegaly patients with invasive macroadenoma: a single center's experience. ( 29429125 )
2018
17
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. ( 29397538 )
2018
18
Molecular evidence and clinical importance of I^-arrestins expression in patients with acromegaly. ( 29377493 )
2018
19
Pachydermoperiostosis Mimicking Acromegaly: A Case Report. ( 29854639 )
2018
20
MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. ( 29339530 )
2018
21
Characteristics of the upper respiratory tract in patients with acromegaly and correlations with obstructive sleep apnoea/hypopnea syndrome. ( 29852361 )
2018
22
Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study. ( 29853879 )
2018
23
An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations. ( 29678281 )
2018
24
Cardiovascular Risk Factors in Acromegaly: What's the Impact of Disease Control? ( 29365332 )
2018
25
Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery. ( 29417401 )
2018
26
Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center. ( 29404901 )
2018
27
COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL. ( 29949429 )
2018
28
Automatic Detection of Acromegaly From Facial Photographs Using Machine Learning Methods. ( 29269039 )
2018
29
Anaesthetic management and complications during hypophysectomy in 37 cats with acromegaly. ( 29848149 )
2018
30
Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5I+-reductase inhibitors: A 15-year longitudinal case report. ( 29405593 )
2018
31
Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile? ( 29790118 )
2018
32
The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels. ( 29931465 )
2018
33
Elevated serum IGF-1 level enhances retinal and choroidal thickness in untreated acromegaly patients. ( 29318448 )
2018
34
Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naA^ve to somatostatin-receptor ligands: analysis of three multicenter clinical trials. ( 29357081 )
2018
35
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. ( 29797214 )
2018
36
Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. ( 29764907 )
2018
37
Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism? ( 30415402 )
2018
38
Evaluation of the natural course of thyroid nodules in patients with acromegaly. ( 30430336 )
2018
39
Long-term management and postmortem examination in a diabetic cat with acromegaly treated with two courses of radiation therapy. ( 30449819 )
2018
40
Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. ( 30474822 )
2018
41
Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment. ( 30482010 )
2018
42
Letter to the Editor. Upfront GKS for Cushing's disease and acromegaly: is it suitable? ( 30485181 )
2018
43
GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly. ( 30488289 )
2018
44
Role of stereotactic radiosurgery in the treatment of acromegaly. ( 30504954 )
2018
45
Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. ( 30506213 )
2018
46
Precision medicine in the treatment of acromegaly. ( 30531695 )
2018
47
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. ( 30535537 )
2018
48
Hypertension is Common in Patients with Newly Diagnosed Acromegaly and is Independently Associated with Renal Resistive Index. ( 30535798 )
2018
49
3D Facial Analysis in Acromegaly: Gender-Specific Features and Clinical Correlations. ( 30555420 )
2018
50
Has acromegaly been diagnosed earlier? ( 29113856 )
2018

Variations for Acromegaly

ClinVar genetic disease variations for Acromegaly:

6 (show top 50) (show all 135)
# Gene Variation Type Significance SNP ID Assembly Location
1 AIP NM_003977.3(AIP): c.40C> T (p.Gln14Ter) single nucleotide variant Pathogenic rs104894194 GRCh37 Chromosome 11, 67250669: 67250669
2 AIP NM_003977.3(AIP): c.40C> T (p.Gln14Ter) single nucleotide variant Pathogenic rs104894194 GRCh38 Chromosome 11, 67483198: 67483198
3 AIP NM_003977.3(AIP): c.469-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs267606555 GRCh37 Chromosome 11, 67257508: 67257508
4 AIP NM_003977.3(AIP): c.469-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs267606555 GRCh38 Chromosome 11, 67490037: 67490037
5 AIP NM_003977.3(AIP): c.910C> T (p.Arg304Ter) single nucleotide variant Pathogenic rs104894195 GRCh37 Chromosome 11, 67258381: 67258381
6 AIP NM_003977.3(AIP): c.910C> T (p.Arg304Ter) single nucleotide variant Pathogenic rs104894195 GRCh38 Chromosome 11, 67490910: 67490910
7 AIP NM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del) deletion Pathogenic/Likely pathogenic rs267606567 GRCh37 Chromosome 11, 67250695: 67250700
8 AIP NM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del) deletion Pathogenic/Likely pathogenic rs267606567 GRCh38 Chromosome 11, 67483224: 67483229
9 AIP NM_003977.3(AIP): c.824dupA (p.His275Glnfs) duplication Pathogenic/Likely pathogenic rs267606580 GRCh37 Chromosome 11, 67258295: 67258295
10 AIP NM_003977.3(AIP): c.824dupA (p.His275Glnfs) duplication Pathogenic/Likely pathogenic rs267606580 GRCh38 Chromosome 11, 67490824: 67490824
11 AIP NM_003977.3(AIP): c.542delT (p.Ile182Serfs) deletion Pathogenic/Likely pathogenic rs267606559 GRCh37 Chromosome 11, 67257582: 67257582
12 AIP NM_003977.3(AIP): c.542delT (p.Ile182Serfs) deletion Pathogenic/Likely pathogenic rs267606559 GRCh38 Chromosome 11, 67490111: 67490111
13 AIP NM_003977.3(AIP): c.804C> A (p.Tyr268Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908356 GRCh37 Chromosome 11, 67258275: 67258275
14 AIP NM_003977.3(AIP): c.804C> A (p.Tyr268Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908356 GRCh38 Chromosome 11, 67490804: 67490804
15 AIP NM_003977.3(AIP): c.911G> A (p.Arg304Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104894190 GRCh37 Chromosome 11, 67258382: 67258382
16 AIP NM_003977.3(AIP): c.911G> A (p.Arg304Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104894190 GRCh38 Chromosome 11, 67490911: 67490911
17 AIP NM_003977.3(AIP): c.64C> T (p.Arg22Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908357 GRCh37 Chromosome 11, 67250693: 67250693
18 AIP NM_003977.3(AIP): c.64C> T (p.Arg22Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908357 GRCh38 Chromosome 11, 67483222: 67483222
19 AIP NM_003977.2(AIP): c.-1212_279+578del deletion Likely pathogenic GRCh37 Chromosome 11, 67249418: 67255234
20 AIP NM_003977.2(AIP): c.-1212_279+578del deletion Likely pathogenic GRCh38 Chromosome 11, 67481947: 67487763
21 AIP NM_003977.3(AIP): c.-5G> C single nucleotide variant Likely benign rs267606562 GRCh37 Chromosome 11, 67250625: 67250625
22 AIP NM_003977.3(AIP): c.-5G> C single nucleotide variant Likely benign rs267606562 GRCh38 Chromosome 11, 67483154: 67483154
23 AIP NM_003977.2(AIP): c.(?_1)_(*_?)del deletion Likely pathogenic
24 AIP NM_003977.3(AIP): c.100-1025_279+357del1562 deletion Likely pathogenic GRCh37 Chromosome 11, 67253452: 67255013
25 AIP NM_003977.3(AIP): c.100-1025_279+357del1562 deletion Likely pathogenic GRCh38 Chromosome 11, 67485981: 67487542
26 AIP NM_003977.3(AIP): c.135C> T (p.Asp45=) single nucleotide variant Likely benign rs181969066 GRCh37 Chromosome 11, 67254512: 67254512
27 AIP NM_003977.3(AIP): c.135C> T (p.Asp45=) single nucleotide variant Likely benign rs181969066 GRCh38 Chromosome 11, 67487041: 67487041
28 AIP NM_003977.3(AIP): c.138_161del24 (p.Gly47_Arg54del) deletion Likely pathogenic rs267606537 GRCh37 Chromosome 11, 67254515: 67254538
29 AIP NM_003977.3(AIP): c.138_161del24 (p.Gly47_Arg54del) deletion Likely pathogenic rs267606537 GRCh38 Chromosome 11, 67487044: 67487067
30 AIP NM_003977.3(AIP): c.145G> A (p.Val49Met) single nucleotide variant Conflicting interpretations of pathogenicity rs1063385 GRCh37 Chromosome 11, 67254522: 67254522
31 AIP NM_003977.3(AIP): c.145G> A (p.Val49Met) single nucleotide variant Conflicting interpretations of pathogenicity rs1063385 GRCh38 Chromosome 11, 67487051: 67487051
32 AIP NM_003977.3(AIP): c.166C> A (p.Arg56Ser) single nucleotide variant Likely pathogenic rs267606538 GRCh37 Chromosome 11, 67254543: 67254543
33 AIP NM_003977.3(AIP): c.166C> A (p.Arg56Ser) single nucleotide variant Likely pathogenic rs267606538 GRCh38 Chromosome 11, 67487072: 67487072
34 AIP NM_003977.3(AIP): c.174G> C (p.Lys58Asn) single nucleotide variant Uncertain significance rs267606539 GRCh37 Chromosome 11, 67254551: 67254551
35 AIP NM_003977.3(AIP): c.174G> C (p.Lys58Asn) single nucleotide variant Uncertain significance rs267606539 GRCh38 Chromosome 11, 67487080: 67487080
36 AIP NM_003977.3(AIP): c.241C> T (p.Arg81Ter) single nucleotide variant Pathogenic rs267606541 GRCh37 Chromosome 11, 67254618: 67254618
37 AIP NM_003977.3(AIP): c.241C> T (p.Arg81Ter) single nucleotide variant Pathogenic rs267606541 GRCh38 Chromosome 11, 67487147: 67487147
38 AIP NM_003977.3(AIP): c.244_248delGAAGG (p.Glu82Glyfs) deletion Likely pathogenic rs267606542 GRCh37 Chromosome 11, 67254621: 67254625
39 AIP NM_003977.3(AIP): c.244_248delGAAGG (p.Glu82Glyfs) deletion Likely pathogenic rs267606542 GRCh38 Chromosome 11, 67487150: 67487154
40 AIP NM_003977.3(AIP): c.249G> T (p.Gly83=) single nucleotide variant Likely pathogenic rs104895072 GRCh37 Chromosome 11, 67254626: 67254626
41 AIP NM_003977.3(AIP): c.249G> T (p.Gly83=) single nucleotide variant Likely pathogenic rs104895072 GRCh38 Chromosome 11, 67487155: 67487155
42 AIP NM_003977.3(AIP): c.250G> A (p.Glu84Lys) single nucleotide variant Likely pathogenic rs267606543 GRCh37 Chromosome 11, 67254627: 67254627
43 AIP NM_003977.3(AIP): c.250G> A (p.Glu84Lys) single nucleotide variant Likely pathogenic rs267606543 GRCh38 Chromosome 11, 67487156: 67487156
44 AIP NM_003977.3(AIP): c.280-1G> A single nucleotide variant Likely pathogenic rs267606544 GRCh37 Chromosome 11, 67256737: 67256737
45 AIP NM_003977.3(AIP): c.280-1G> A single nucleotide variant Likely pathogenic rs267606544 GRCh38 Chromosome 11, 67489266: 67489266
46 AIP NM_003977.3(AIP): c.286_287delGT (p.Val96Profs) deletion Likely pathogenic rs267606545 GRCh37 Chromosome 11, 67256744: 67256745
47 AIP NM_003977.3(AIP): c.286_287delGT (p.Val96Profs) deletion Likely pathogenic rs267606545 GRCh38 Chromosome 11, 67489273: 67489274
48 AIP NM_003977.3(AIP): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs267606546 GRCh37 Chromosome 11, 67250631: 67250631
49 AIP NM_003977.3(AIP): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs267606546 GRCh38 Chromosome 11, 67483160: 67483160
50 AIP NM_003977.3(AIP): c.308A> G (p.Lys103Arg) single nucleotide variant Likely pathogenic rs267606548 GRCh37 Chromosome 11, 67256766: 67256766

Expression for Acromegaly

Search GEO for disease gene expression data for Acromegaly.

Pathways for Acromegaly

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 GHRH GHRL GNAS IGF1 IGF2 INS
2
Show member pathways
13.66 GH1 GHRL IGF1 IGF2 IGFBP1 IGFBP3
3
Show member pathways
13.36 GH1 GHR GHRH GNAS IGF1 IGF2
4
Show member pathways
12.87 GH1 GHRH GNAS IGF1 IGF2 INS
5
Show member pathways
12.75 GH1 GHR GNAS IGF1 IGF2 INS
6
Show member pathways
12.74 GH1 GHR IGF1 IGFBP3 INS
7
Show member pathways
12.67 GH1 GHR GHRH GHRL GNAS POMC
8
Show member pathways
12.26 AIP GNAS MEN1 POMC
9
Show member pathways
12.22 IGF1 IGF2 IGFBP1 IGFBP3
10
Show member pathways
12.02 GHRL GNAS SSTR1 SSTR2 SSTR5
11
Show member pathways
11.91 GH1 GHRL IGF1 INS POMC
12 11.78 IGF1 IGFBP3 INS
13 11.49 GH1 GHRH GNAS IGF1 IGF2
14 11.4 IGF1 IGF2 INS
15 11.32 GNAS IGF1 INS
16 11.27 GH1 GHR IGF1 IGF2
17
Show member pathways
11.22 GH1 GHR PRL
18 10.86 GH1 GHRH GNAS IGF1 IGF2
19 10.58 IGF1 IGF2 IGFBP1 IGFBP3

GO Terms for Acromegaly

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 GH1 GHR GHRH GHRL IGF1 IGF2
2 endoplasmic reticulum lumen GO:0005788 9.72 GHRL IGFBP1 IGFBP3 INS MEN1
3 secretory granule GO:0030141 9.61 POMC PRL TRH
4 extracellular region GO:0005576 9.47 GH1 GHR GHRH GHRL GNAS IGF1
5 insulin-like growth factor ternary complex GO:0042567 9.4 IGF1 IGFBP3
6 insulin-like growth factor binding protein complex GO:0016942 9.37 IGF1 IGFBP3
7 endosome lumen GO:0031904 9.33 GH1 INS PRL
8 growth hormone receptor complex GO:0070195 9.26 GH1 GHR

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.95 IGFBP3 MEN1 SST SSTR1 SSTR2 SSTR5
2 G protein-coupled receptor signaling pathway GO:0007186 9.9 GHRH GHRL GNAS GPR101 INS POMC
3 cell-cell signaling GO:0007267 9.89 GHRH INS POMC SST TRH
4 positive regulation of MAPK cascade GO:0043410 9.87 IGF1 IGF2 IGFBP3 INS
5 neuropeptide signaling pathway GO:0007218 9.83 POMC SSTR1 SSTR2 SSTR5
6 insulin receptor signaling pathway GO:0008286 9.82 IGF2 IGFBP1 INS
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.82 GH1 IGF1 INS
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 GH1 GHR IGF1
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.8 SSTR1 SSTR2 SSTR5
10 glucose metabolic process GO:0006006 9.8 GHRL IGF2 INS
11 cellular protein metabolic process GO:0044267 9.8 IGF1 IGF2 IGFBP1 IGFBP3 INS MEN1
12 response to nutrient levels GO:0031667 9.79 GH1 GHRL PRL
13 hormone-mediated signaling pathway GO:0009755 9.77 GHR GHRL TRH
14 positive regulation of insulin secretion GO:0032024 9.76 GHRH GHRL TRH
15 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 GH1 GHR IGF1 IGF2
16 regulation of multicellular organism growth GO:0040014 9.72 GHR IGF1 PRL
17 positive regulation of mitotic nuclear division GO:0045840 9.71 IGF1 IGF2 INS
18 positive regulation of JAK-STAT cascade GO:0046427 9.69 GH1 GHR PRL
19 positive regulation of insulin receptor signaling pathway GO:0046628 9.67 IGF2 INS
20 insulin-like growth factor receptor signaling pathway GO:0048009 9.66 GHR IGF1
21 growth hormone receptor signaling pathway GO:0060396 9.65 GH1 GHR
22 positive regulation of growth GO:0045927 9.65 GH1 GHRL
23 positive regulation of growth hormone secretion GO:0060124 9.64 GHRH GHRL
24 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.62 GH1 GHRH IGF1 IGFBP3
25 growth hormone secretion GO:0030252 9.61 GHRH GHRL
26 negative regulation of feeding behavior GO:2000252 9.61 INS TRH
27 positive regulation of glycogen biosynthetic process GO:0045725 9.61 IGF1 IGF2 INS
28 positive regulation of circadian sleep/wake cycle, non-REM sleep GO:0046010 9.59 GHRH GHRL
29 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 GH1 GHR PRL
30 positive regulation of lactation GO:1903489 9.56 GHRH PRL
31 somatostatin signaling pathway GO:0038170 9.54 SSTR1 SSTR2 SSTR5
32 positive regulation of multicellular organism growth GO:0040018 9.35 GH1 GHR GHRH GHRL IGF2
33 regulation of signaling receptor activity GO:0010469 9.32 GH1 GHRH GHRL IGF1 IGF2 INS
34 signal transduction GO:0007165 10.23 GNAS GPR101 IGF1 IGFBP1 POMC SSTR1
35 positive regulation of cell proliferation GO:0008284 10.06 GHRH IGF1 IGF2 INS PRL

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor binding GO:0001664 9.65 GHRL GNAS POMC
2 growth factor binding GO:0019838 9.61 GHR IGFBP1 IGFBP3
3 insulin receptor binding GO:0005158 9.5 IGF1 IGF2 INS
4 insulin-like growth factor I binding GO:0031994 9.49 IGFBP1 IGFBP3
5 insulin-like growth factor II binding GO:0031995 9.46 IGFBP1 IGFBP3
6 neuropeptide binding GO:0042923 9.43 SSTR1 SSTR2 SSTR5
7 growth hormone-releasing hormone activity GO:0016608 9.4 GHRH GHRL
8 prolactin receptor binding GO:0005148 9.37 GH1 PRL
9 somatostatin receptor activity GO:0004994 9.33 SSTR1 SSTR2 SSTR5
10 hormone activity GO:0005179 9.32 GH1 GHRH GHRL IGF1 IGF2 INS
11 insulin-like growth factor receptor binding GO:0005159 9.26 GNAS IGF1 IGF2 INS

Sources for Acromegaly

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....